Luminopia Inc.

Why Luminopia

Watch TV as Treatment

Say goodbye to eye patches and eye drops — the future of amblyopia treatment is here. With Luminopia, children can watch TV to improve their vision. Whether it’s Spongebob, Wild Kratts, or Sesame Street, all kids have to do is pick a video, sit back, and watch. Our software algorithms take care of the rest, by presenting the images differently to each eye and stimulating parts of the brain responsible for vision.


Luminopia is simple, engaging, and effective


For physicians, all you have to do is send an e-Rx or fax prescription to our retail pharmacy partner and we will take care of the rest - no need to think about inventory, payment, or anything else. For patients, we provide everything you need to get started, including a VR headset with access to the treatment software.


Patients can choose from over 700 hours of popular TV shows and movies to watch during treatment. That's why compliance with Luminopia was around double that of patching in our clinical trials. The recommended dose is lighter too - it's 1 hour per day, 6 days per week.


Luminopia is based in cutting-edge neuroscience and has been studied in three clinical trials, with similar rigor as a new pharmaceutical product. Children can experience significant vision improvement within a month, and the therapy works in both new patients and those that have been through patching or atropine drops.

Rooted in Science

Traditional amblyopia therapies like patching and atropine drops punish the stronger eye to force the brain to pay attention to the weaker eye. But they don’t teach the eyes how to work together properly.

Luminopia is different. Luminopia is built on decades of cutting-edge research done by leading clinicians and neuroscientists at Boston Children’s Hospital and MIT.

Our software algorithms use a dual-action mechanism to rebalance input between the eyes, and encourage the brain to combine the images from both eyes. We harness the power of VR headsets to deliver treatment within a controlled environment with no distractions.

View Supporting Literature

Clinically Proven

Luminopia has been validated through a similar development process as a new pharmaceutical product. The technology has been evaluated in 3 clinical trials, with 200+ patients at more than 20 hospitals and research sites across the US, including a gold standard, randomized controlled Phase 3 trial which demonstrated the safety and efficacy of the therapy for children aged 4-7 years.

Patient Adherence


compliance with full dose of 1 hr/day, 6 days/week over 12 weeks

Treatment Benefit


of kids experience vision improvement after treatment

Patient Preference


prefer Luminopia over patching


Our Clinical Partners

The technology behind Luminopia was developed and tested at leading academic institutions across the country.

partner logo
partner logo
partner logo
partner logo

Our Media partners

We’ve partnered with several of the most beloved entertainment companies to create a captivating experience for children.

partner logo
partner logo
partner logo
partner logo


1 - Xiao, S., Gaier, E. D., Wu, H. C., Angjeli, E., Nuth, P. L., Bohra, L. I., Miller, A. M., Mazow, M. L., Stout, A. U., Morse, C. L., Blumenfeld, L. C., Glaser, S. R., Crouch, E., Ekdawi, N. S., Lyon, D. W., Silbert, D. I., & Hunter, D. G. (2021). Digital therapeutic improves visual acuity and encourages high adherence in amblyopic children in open-label pilot study. JAAPOS, 25(2).

2 - Xiao, S., Angjeli, E., Wu, H. C., Gaier, E. D., Gomez, S., Travers, D. A., Binenbaum, G., Langer, R., Hunter, D. G., & Repka, M. X. (2022). Randomized controlled trial of a dichoptic digital therapeutic for Amblyopia. Ophthalmology, 129(1), 77–85.

3 - Wallace, M. P., Stewart, C. E., Moseley, M. J., Stephens, D. A., Fielder, A. R., Monitored Occlusion Treatment Amblyopia Study (MOTAS) Cooperatives, & Randomized Occlusion Treatment Amblyopia Study (ROTAS) Cooperatives (2013). Compliance with occlusion therapy for childhood amblyopia. Investigative ophthalmology & visual science, 54(9), 6158–6166.

Indications, Safety and Warnings


Luminopia is a software-only digital therapeutic designed to be used with commercially available Head-Mounted Displays (HMDs) which are compatible with the software application. Luminopia is indicated for improvement in visual acuity in amblyopia patients, aged 4-7, associated with anisometropia and/or with mild strabismus, having received treatment instructions (frequency and duration) as prescribed by a trained eye-care professional. Luminopia is intended for both previously treated and untreated patients; however, patients with more than 12 months of prior treatment (other than refractive correction) have not been studied. Luminopia is intended to be used as an adjunct to full-time refractive correction, such as glasses, which should also be worn under the HMD during Luminopia therapy. Luminopia is intended for Prescription Use Only, in an at-home environment.


In the Luminopia pivotal trial, 14 patients (25%) experienced adverse events in the treatment group vs. 8 (14%) in the control group. Ocular AEs were reported in 6 (11%) patients in the treatment group and 8 (14%) patients in the control. No serious adverse events (AEs) were reported. The most frequent non-serious AE potentially related to Luminopia was headache (14.3%), for which all cases were graded as mild, transient, and resolved without sequelae.


Rx only: Federal law restricts this device on the order of a trained eye-care professional.

Safety and effectiveness of Luminopia beyond 12 weeks is unknown. The long-term effects of HMD use in patients 4-7 years of age are unknown. Patients with a history of light-induced seizures, or serious medical conditions, should contact a doctor before using Luminopia. Patients should only use Luminopia while wearing their prescribed glasses under the HMD. Patients should stop using Luminopia and contact a doctor if they experience a new or worsened eye-turn, or double vision. Patients with an interpupillary distance of less than 52 mm should not use Luminopia.

Sign up to stay updated on our launch

I am a:

Privacy Policy

Copyright 2023 © Luminopia, Inc. All rights reserved.